Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TNFerade: Phase II/III amended

Based on discussions with FDA, GenVec changed the protocol for the ongoing Phase II/III

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE